按种族和族裔划分的乳腺筛查异常后活检时间的多水平相关因素
这项前瞻性队列研究纳入2009至2019年美国6州109家影像机构的45186名40至79岁乳腺筛查异常女性,分析种族和族裔与筛查异常至活检时间的关系。调整多水平因素后,黑人女性在90天内未活检的风险仍持续存在(RR 1.20,95%CI 1.08-1.34),提示未测量因素如系统性种族主义可能影响及时诊断。
要点
- 筛查异常建议活检的乳腺钼靶中,34.6%在30天内未解决,16.2%在60天内未解决,12.2%在90天内未解决。
- 与白人女性相比,亚裔、黑人和西班牙裔女性30天和60天未活检风险升高。
- 调整多水平因素后,黑人女性90天未活检风险仍持续存在(RR 1.20,95%CI 1.08-1.34)。
核心结论
- 在调整多水平因素后,黑人女性最可能经历诊断解决延迟。
- 这些结果提示调整多水平因素并未完全解释乳腺活检时间的差异,未测量因素如系统性种族主义和其他医疗保健系统因素可能影响及时诊断。
研究设计与样本
- 前瞻性队列研究,使用2009至2019年美国6州109家影像机构中40至79岁乳腺筛查异常女性的数据。
- 共纳入45186名女性(筛查时中位[IQR]年龄56[48-65]岁)的46185次筛查异常乳腺钼靶。
- 数据分析时间为2021年2月21日至11月4日。
主要发现
- 筛查异常建议活检的乳腺钼靶中,15969次(34.6%)未在30天内解决,7493次(16.2%)未在60天内解决,5634次(12.2%)未在90天内解决。
- 与白人女性相比,亚裔女性30天未活检风险升高(RR 1.66,95%CI 1.31-2.10),60天风险升高(RR 1.58,95%CI 1.15-2.18)。
- 与白人女性相比,黑人女性30天未活检风险升高(RR 1.52,95%CI 1.30-1.78),60天风险升高(RR 1.39,95%CI 1.22-1.60)。
- 与白人女性相比,西班牙裔女性30天未活检风险升高(RR 1.50,95%CI 1.24-1.81),60天风险升高(RR 1.38,95%CI 1.11-1.71)。
- 未调整的90天未活检风险仅在黑人女性中持续存在(RR 1.28,95%CI 1.11-1.47);依次调整个体、社区和医疗保健水平因素(不包括筛查机构)后,黑人女性90天未活检风险为RR 1.27(95%CI 1.12-1.44);额外调整筛查机构后,风险为RR 1.20(95%CI 1.08-1.34)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Diagnostic delays in breast cancer detection may be associated with later-stage disease and higher anxiety, but data on multilevel factors associated with diagnostic delay are limited. OBJECTIVE: To evaluate individual-, neighborhood-, and health care-level factors associated with differences in time from abnormal screening to biopsy among racial and ethnic groups. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used data from women aged 40 to 79 years who had abnormal results in screening mammograms conducted in 109 imaging facilities across 6 US states between 2009 and 2019. Data were analyzed from February 21 to November 4, 2021. EXPOSURES: Individual-level factors included self-reported race and ethnicity, age, family history of breast cancer, breast density, previous breast biopsy, and time since last mammogram; neighborhood-level factors included geocoded education and income based on residential zip codes and rurality; and health care-level factors included mammogram modality, screening facility academic affiliation, and facility onsite biopsy service availability. Data were also assessed by examination year. MAIN OUTCOME AND MEASURES: The main outcome was unadjusted and adjusted relative risk (RR) of no biopsy within 30, 60, and 90 days using sequential log-binomial regression models. A secondary outcome was unadjusted and adjusted median time to biopsy using accelerated failure time models. RESULTS: A total of 45 186 women (median [IQR] age at screening, 56 [48-65] years) with 46 185 screening mammograms with abnormal results were included. Of screening mammograms with abnormal results recommended for biopsy, 15 969 (34.6%) were not resolved within 30 days, 7493 (16.2%) were not resolved within 60 days, and 5634 (12.2%) were not resolved within 90 days. Compared with White women, there was increased risk of no biopsy within 30 and 60 days for Asian (30 days: RR, 1.66; 95% CI, 1.31-2.10; 60 days: RR, 1.58; 95% CI, 1.15-2.18), Black (30 days: RR, 1.52; 95% CI, 1.30-1.78; 60 days: 1.39; 95% CI, 1.22-1.60), and Hispanic (30 days: RR, 1.50; 95% CI, 1.24-1.81; 60 days: 1.38; 95% CI, 1.11-1.71) women; however, the unadjusted risk of no biopsy within 90 days only persisted significantly for Black women (RR, 1.28; 95% CI, 1.11-1.47). Sequential adjustment for selected individual-, neighborhood-, and health care-level factors, exclusive of screening facility, did not substantially change the risk of no biopsy within 90 days for Black women (RR, 1.27; 95% CI, 1.12-1.44). After additionally adjusting for screening facility, the increased risk for Black women persisted but showed a modest decrease (RR, 1.20; 95% CI, 1.08-1.34). CONCLUSIONS AND RELEVANCE: In this cohort study involving a diverse cohort of US women recommended for biopsy after abnormal results on screening mammography, Black women were the most likely to experience delays to diagnostic resolution after adjusting for multilevel factors. These results suggest that adjustment for multilevel factors did not entirely account for differences in time to breast biopsy, but unmeasured factors, such as systemic racism and other health care system factors, may impact timely diagnosis.
引用
- Lawson MB, Bissell MCS, Miglioretti DL, et al. Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity. JAMA Oncol. 2022. PMID: 35737381. doi:10.1001/jamaoncol.2022.1990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。